tetano
Editor, Senior Moderator
Clin Microbiol Infect
. 2021 Jun 7;S1198-743X(21)00281-0.
doi: 10.1016/j.cmi.2021.05.033. Online ahead of print.
Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients
Maddalena Peghin[SUP] 1 [/SUP], Alvisa Palese[SUP] 2 [/SUP], Margherita Venturini[SUP] 2 [/SUP], Maria De Martino[SUP] 3 [/SUP], Valentina Gerussi[SUP] 4 [/SUP], Elena Graziano[SUP] 4 [/SUP], Giulia Bontempo[SUP] 4 [/SUP], Francesco Marrella[SUP] 4 [/SUP], Alberto Tommasini[SUP] 5 [/SUP], Martina Fabris[SUP] 6 [/SUP], Francesco Curcio[SUP] 7 [/SUP], Miriam Isola[SUP] 3 [/SUP], Carlo Tascini[SUP] 4 [/SUP]
Affiliations
Abstract
Objectives: To assess the prevalence of and factors associated with Post-Coronavirus Disease 2019 (COVID-19) syndrome six months after the onset.
Methods: A bidirectional prospective study. Interviews investigated symptoms potentially associated with COVID-19 six months after the disease onset of all consecutive adult in- and out-patients with COVID-19 attending Udine Hospital (Italy) from March to May 2020. IgG antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were also evaluated six months after the onset of symptoms, at the time of the interview.
Results: A total of 599 individuals were included (320 female, 53.4%; mean age 53 years, SD 15.8) and interviewed 187 days (22 SD) after the onset. The prevalence of post-COVID-19 syndrome was 40.2% (241/599). The presence of IgG antibodies was significantly associated with the occurrence of post-COVID-19 syndrome (OR 2.56, 95% CI 1.48-4.38, p = 0.001) and median SARS-CoV-2 IgG titres were significantly higher in long-haulers than in patients without symptoms (42.1, IQR 17.1-78.4 vs. 29.1, IQR 12.1-54.2 kAU/L, p = 0.004). Female gender (OR 1.55, 95% CI 1.05-2.27), a proportional increase in the number of symptoms at the onset of COVID-19 (OR 1.81, 95% CI 1.59-2.05) and ICU admission OR 3.10, 95% CI 1.18-8.11) were all independent risk factors for post-COVID-19 syndrome. The same predictors also emerged in a subgroup of 231 patients with the serological follow-up available at the time of the interview alongside the proportional increase in anti-SARS-CoV-2 IgG (OR 1.01, 95% CI 1.00-1.02, p = 0.04).
Conclusions: Prospective follow-up could be offered to specific subgroups of COVID-10 patients, to identify typical symptoms and persistently high anti-SARS-CoV-2 IgG titers as a means of early detection of post-COVID-19 long-term sequelae.
Keywords: COVID survivors; COVID-19; Chronic COVID; Lasting haulers; Long COVID; SARS-CoV-2 antibodies; SARS-CoV-2 serology; post-COVID syndrome.
. 2021 Jun 7;S1198-743X(21)00281-0.
doi: 10.1016/j.cmi.2021.05.033. Online ahead of print.
Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients
Maddalena Peghin[SUP] 1 [/SUP], Alvisa Palese[SUP] 2 [/SUP], Margherita Venturini[SUP] 2 [/SUP], Maria De Martino[SUP] 3 [/SUP], Valentina Gerussi[SUP] 4 [/SUP], Elena Graziano[SUP] 4 [/SUP], Giulia Bontempo[SUP] 4 [/SUP], Francesco Marrella[SUP] 4 [/SUP], Alberto Tommasini[SUP] 5 [/SUP], Martina Fabris[SUP] 6 [/SUP], Francesco Curcio[SUP] 7 [/SUP], Miriam Isola[SUP] 3 [/SUP], Carlo Tascini[SUP] 4 [/SUP]
Affiliations
- PMID: 34111579
- PMCID: PMC8180450
- DOI: 10.1016/j.cmi.2021.05.033
Abstract
Objectives: To assess the prevalence of and factors associated with Post-Coronavirus Disease 2019 (COVID-19) syndrome six months after the onset.
Methods: A bidirectional prospective study. Interviews investigated symptoms potentially associated with COVID-19 six months after the disease onset of all consecutive adult in- and out-patients with COVID-19 attending Udine Hospital (Italy) from March to May 2020. IgG antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were also evaluated six months after the onset of symptoms, at the time of the interview.
Results: A total of 599 individuals were included (320 female, 53.4%; mean age 53 years, SD 15.8) and interviewed 187 days (22 SD) after the onset. The prevalence of post-COVID-19 syndrome was 40.2% (241/599). The presence of IgG antibodies was significantly associated with the occurrence of post-COVID-19 syndrome (OR 2.56, 95% CI 1.48-4.38, p = 0.001) and median SARS-CoV-2 IgG titres were significantly higher in long-haulers than in patients without symptoms (42.1, IQR 17.1-78.4 vs. 29.1, IQR 12.1-54.2 kAU/L, p = 0.004). Female gender (OR 1.55, 95% CI 1.05-2.27), a proportional increase in the number of symptoms at the onset of COVID-19 (OR 1.81, 95% CI 1.59-2.05) and ICU admission OR 3.10, 95% CI 1.18-8.11) were all independent risk factors for post-COVID-19 syndrome. The same predictors also emerged in a subgroup of 231 patients with the serological follow-up available at the time of the interview alongside the proportional increase in anti-SARS-CoV-2 IgG (OR 1.01, 95% CI 1.00-1.02, p = 0.04).
Conclusions: Prospective follow-up could be offered to specific subgroups of COVID-10 patients, to identify typical symptoms and persistently high anti-SARS-CoV-2 IgG titers as a means of early detection of post-COVID-19 long-term sequelae.
Keywords: COVID survivors; COVID-19; Chronic COVID; Lasting haulers; Long COVID; SARS-CoV-2 antibodies; SARS-CoV-2 serology; post-COVID syndrome.